This website is accessible to all versions of every browser. However, you are seeing this message because your browser does not support basic Web standards, and does not properly display the site's design details. Please consider upgrading to a more modern browser. (Learn More).

You are here: home > business > local

Biolex And Medarex Sign Research Collaboration Agreement

Posted Monday, February 7, 2005

e-mail E-mail this page   print Printer-friendly page

Pittsboro - Biolex, Inc., a privately held protein therapeutics company, today announced the signing of a new agreement with Medarex, Inc. , an antibody therapeutics company, to create a commercial line for an undisclosed Medarex monoclonal antibody using the Biolex LEX System™. Including this project, Biolex has a total of eleven partner proteins with five different top-tier partners to date, two of which have already advanced to GLP scale-up production.

"I am excited to be adding another antibody to our Partner Proteins portfolio of products in evaluation using our unique approach to protein production," said Jan Turek, President and CEO of Biolex. "We are pleased that a company such as Medarex, with longstanding monoclonal antibody expertise, sees the potential advantages of using the LEX System™ and recognizes the value of new approaches to protein expression."

Biolex will implement a Commercial Line Creation project using its proprietary LEX System™ for one of Medarex' clinical-stage monoclonal antibodies. At Medarex' option, Biolex may scale-up and manufacture the antibody following the commercial line creation phase. Financial terms of the collaboration have not been disclosed.

 
e-mail E-mail this page
print Printer-friendly page
 
 
 
Biolex And Medarex Sign Research Collaboration Agreement
 
Business

Got Feedback?
Send a letter to the editor.

Subscribe
Sign up for the Chatham Chatlist. Find out what your friends and neighbors are saying about what's going on in Chatham County.

Advertise
Promote your business at chathamjournal.com



Subscribe now: RSS news feed, plus FREE headlines for your site